I. V. Polesko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
I. V. Polesko has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Olga V. Shamsheva
Pirogov Russian National Research Medical University
6 shared publications - E. O. Kochetova
Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
3 shared publications - V. F. Uchaykin
Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
3 shared publications - Vera V. Belyakova
Moscow City Blood Center named after O.K. Gavrilov
3 shared publications - Aleksey A. Khaldin
Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology
2 shared publications - D.A. Abukhaltam Akhmad
Pirogov Russian National Research Medical University
2 shared publications
Latest Publications
- 10 September 2025
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 24 (4)
Modern methods of treatment of latent form of HPV infection: clinical observation
Papillomavirus infection is one of the most common urogenital tract infections with pronounced oncogenic potential. Human papillomavirus (HPV) is associated with the development of cancer of uterine cervix, vagina, vulva, penis and oropharyngeal neoplasms. Despite the fact that anogenital warts are the main clinical manifestation of the infection, a significant number of cases is latent, that complicates diagnosis and early treatment. The article presents a clinical observation of a 25-year-old patient with latent form of papillomavirus infection. PCR testing revealed HPV of 6, 11, 39, 59 and 56 genotypes, including high-risk oncogenic types with no visible clinical manifestations. The patient was treated with recombinant interferon alpha-2b in combination with antioxidants. The control examination 4 weeks after the end of treatment showed complete elimination of the pathogen, that indicates the selected therapy’s efficacy. The mechanism of action of interferon alpha-2b is realized through activation of cellular and humoral immunity, suppression of viral replication and enhancement of phagocyte activity of macrophages. The inclusion of antioxidants (vitamins C and E) potentiates antiviral activity by stabilizing cellular membranes. The presented observation confirms that immunomodulatory therapy using recombinant interferons in combination with antioxidants is an effective method for treatment of latent HPV infection, providing elimination of the causative agent and reducing the risk of developing HPV-associated cancers.
- 10 September 2025
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 24 (4)
Modern methods of treatment of latent form of HPV infection: clinical observation
Papillomavirus infection is one of the most common urogenital tract infections with pronounced oncogenic potential. Human papillomavirus (HPV) is associated with the development of cancer of uterine cervix, vagina, vulva, penis and oropharyngeal neoplasms. Despite the fact that anogenital warts are the main clinical manifestation of the infection, a significant number of cases is latent, that complicates diagnosis and early treatment. The article presents a clinical observation of a 25-year-old patient with latent form of papillomavirus infection. PCR testing revealed HPV of 6, 11, 39, 59 and 56 genotypes, including high-risk oncogenic types with no visible clinical manifestations. The patient was treated with recombinant interferon alpha-2b in combination with antioxidants. The control examination 4 weeks after the end of treatment showed complete elimination of the pathogen, that indicates the selected therapy’s efficacy. The mechanism of action of interferon alpha-2b is realized through activation of cellular and humoral immunity, suppression of viral replication and enhancement of phagocyte activity of macrophages. The inclusion of antioxidants (vitamins C and E) potentiates antiviral activity by stabilizing cellular membranes. The presented observation confirms that immunomodulatory therapy using recombinant interferons in combination with antioxidants is an effective method for treatment of latent HPV infection, providing elimination of the causative agent and reducing the risk of developing HPV-associated cancers.
- 22 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 23 (5)
Improvement of therapy of papillomavirus infection latent forms
Background. The management of patients with asymptomatic papillomavirus infection is still a controversial issue. Previous studies have demonstrated the potential of using immunomodulatory therapy in patients with latent form of HPV-infection. Objective. To optimize therapy in subjects with latent form of papillomavirus infection. Material and methods. Prospective randomized controlled trial included 66 patients infected by HPV. Patients of study group received 3 courses of recombinant IFN alpha-2b with antioxidants by 1 suppository per rectum in a dose of 3 000 000 IU at the bedtime for 10 days. Patients of comparative group remained under medical observation without pharmacological intervention. A qualitative change of HPV content was identified and a quantitative load of HPV was monitored after 4 weeks in patients of both groups. Results. Complete elimination of identified HPV genotypes has been found in 64.5% of patients in the study group, while in the comparison group only in 5.7% (p<0.001). The lack of qualitative changes in HPV content has been revealed in 68.6% of patients in the comparison group and in 12.9% of patients in the study group. The analysis of total viral load after treatment showed a reliable advantage of recombinant IFN alpha-2b: viral load reduced by 3.5 times in the study group, viral load did not change in the comparison group. Conclusion. The study demonstrated a pronounced positive effect of examined drug in the treatment of papillomavirus infection latent forms. Course therapy with recombinant IFN alpha-2b combined with antioxidants allowed to achieve positive dynamics in 80% of patients, including complete HPV elimination in 64.5% and reduction of viral load by 3.5 times.
- 22 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 23 (5)
Improvement of therapy of papillomavirus infection latent forms
Background. The management of patients with asymptomatic papillomavirus infection is still a controversial issue. Previous studies have demonstrated the potential of using immunomodulatory therapy in patients with latent form of HPV-infection. Objective. To optimize therapy in subjects with latent form of papillomavirus infection. Material and methods. Prospective randomized controlled trial included 66 patients infected by HPV. Patients of study group received 3 courses of recombinant IFN alpha-2b with antioxidants by 1 suppository per rectum in a dose of 3 000 000 IU at the bedtime for 10 days. Patients of comparative group remained under medical observation without pharmacological intervention. A qualitative change of HPV content was identified and a quantitative load of HPV was monitored after 4 weeks in patients of both groups. Results. Complete elimination of identified HPV genotypes has been found in 64.5% of patients in the study group, while in the comparison group only in 5.7% (p<0.001). The lack of qualitative changes in HPV content has been revealed in 68.6% of patients in the comparison group and in 12.9% of patients in the study group. The analysis of total viral load after treatment showed a reliable advantage of recombinant IFN alpha-2b: viral load reduced by 3.5 times in the study group, viral load did not change in the comparison group. Conclusion. The study demonstrated a pronounced positive effect of examined drug in the treatment of papillomavirus infection latent forms. Course therapy with recombinant IFN alpha-2b combined with antioxidants allowed to achieve positive dynamics in 80% of patients, including complete HPV elimination in 64.5% and reduction of viral load by 3.5 times.
- 22 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 23 (4)
Effectiveness of recombinant interferon alpha in prevention of candida infection in patients at risk
The article is devoted to the study of effectiveness of interferon alpha-2b with antioxidant (alpha tocopherol acetate and ascorbic acid) in the form of rectal suppositories in the prevention of mucous membrane infection development by fungi of Candida genus in patients at risk. Patients with a proven diagnosis of diabetes mellitus at unreached target levels of glycemia were considered as a risk group. The possibility of including interferon alpha-2b drugs in the course of preventive and rehabilitation procedures in patients with past candida infection or high risk of Candida spp. infection development is being discussed. Background. An increase in the number of cases of Candida spp. resistance to anti-mycotic drugs is of significant concern to the medical community. Type I interferons probably play an important role in protecting the host from Candida albicans, which highlights their potential importance in developing therapeutic strategies against fungal infections. Objective. To assess the effect of using recombinant interferon alpha-2b with antioxidant (alpha tocopherol acetate and ascorbic acid) in the form of rectal suppositories on Candida spp. colonization in patients with risk factors of manifest candidiasis development. Material and methods. A cross-sectional single-center study was performed in groups of patients diagnosed with diabetes mellitus at unreached target levels of glycemia (HbA1c more than 7%, but less than 9%). The main methods of research were following: clinical physical examination with assessment of the mucous membranes of oral cavity and genital organs, as well as quantitative analysis of Candida spp. Colonies in swabs obtained from the mucous membranes of oral cavity and genital cavities. Results. The study shows that the use of rectal suppositories based on recombinant interferon alpha-2b has an effect on Candida spp. Colonization in patients with risk factors of manifest candidiasis development. Conclusion. The study results are consistent with the data of several authors on the effectiveness of interferon alpha regarding fungi of Candida genus and the possibility of using interferon drugs as prophylactic agents to prevent the development of manifest infection process.
- 22 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 23 (4)
Effectiveness of recombinant interferon alpha in prevention of candida infection in patients at risk
The article is devoted to the study of effectiveness of interferon alpha-2b with antioxidant (alpha tocopherol acetate and ascorbic acid) in the form of rectal suppositories in the prevention of mucous membrane infection development by fungi of Candida genus in patients at risk. Patients with a proven diagnosis of diabetes mellitus at unreached target levels of glycemia were considered as a risk group. The possibility of including interferon alpha-2b drugs in the course of preventive and rehabilitation procedures in patients with past candida infection or high risk of Candida spp. infection development is being discussed. Background. An increase in the number of cases of Candida spp. resistance to anti-mycotic drugs is of significant concern to the medical community. Type I interferons probably play an important role in protecting the host from Candida albicans, which highlights their potential importance in developing therapeutic strategies against fungal infections. Objective. To assess the effect of using recombinant interferon alpha-2b with antioxidant (alpha tocopherol acetate and ascorbic acid) in the form of rectal suppositories on Candida spp. colonization in patients with risk factors of manifest candidiasis development. Material and methods. A cross-sectional single-center study was performed in groups of patients diagnosed with diabetes mellitus at unreached target levels of glycemia (HbA1c more than 7%, but less than 9%). The main methods of research were following: clinical physical examination with assessment of the mucous membranes of oral cavity and genital organs, as well as quantitative analysis of Candida spp. Colonies in swabs obtained from the mucous membranes of oral cavity and genital cavities. Results. The study shows that the use of rectal suppositories based on recombinant interferon alpha-2b has an effect on Candida spp. Colonization in patients with risk factors of manifest candidiasis development. Conclusion. The study results are consistent with the data of several authors on the effectiveness of interferon alpha regarding fungi of Candida genus and the possibility of using interferon drugs as prophylactic agents to prevent the development of manifest infection process.
- 18 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 23 (2)
Clinical manifestations of skin and mucosal epithelium lesions in children with mycoplasma infection
A literature review and own data on extrarespiratory manifestations of mycoplasma infection are presented. The role of mixed infection in the analysis of symptoms severity is discussed. The problem of intracellular infections is relevant due to their prevalence, complexity of timely diagnosis as well as complications development. The frequent incidence of diseases caused by mycoplasma among children and adults is confirmed by numerous Russian and foreign data. One of the key factors in the extrarespiratory manifestations’ development of mycoplasma infection is infectious vasculitis. It is known that mycoplasma damages vascular endothelium due to infectious antigens and autoantibodies activity. In addition, it is important to consider that skin lesion may be one of the symptoms of this disease. Frequently the presence of only Mc. Pneumoniae is tested when diagnosing mycoplasma infection, while features of skin and mucosa lesions caused by other mycoplasma are unknown. It has been established, that macrolide-resistant strains of Mc. Pneumoniae are identified, in addition to which extrarespiratory lesions of organs and systems can form without typical symptoms specific to respiratory disease.
- 18 April 2024
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 23 (2)
Clinical manifestations of skin and mucosal epithelium lesions in children with mycoplasma infection
A literature review and own data on extrarespiratory manifestations of mycoplasma infection are presented. The role of mixed infection in the analysis of symptoms severity is discussed. The problem of intracellular infections is relevant due to their prevalence, complexity of timely diagnosis as well as complications development. The frequent incidence of diseases caused by mycoplasma among children and adults is confirmed by numerous Russian and foreign data. One of the key factors in the extrarespiratory manifestations’ development of mycoplasma infection is infectious vasculitis. It is known that mycoplasma damages vascular endothelium due to infectious antigens and autoantibodies activity. In addition, it is important to consider that skin lesion may be one of the symptoms of this disease. Frequently the presence of only Mc. Pneumoniae is tested when diagnosing mycoplasma infection, while features of skin and mucosa lesions caused by other mycoplasma are unknown. It has been established, that macrolide-resistant strains of Mc. Pneumoniae are identified, in addition to which extrarespiratory lesions of organs and systems can form without typical symptoms specific to respiratory disease.
- 14 February 2024
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 23 (1)
Bullous scleroderma: experience of combined therapy
Scleroderma is an autoimmune disease manifested by damage to the connective tissue. The disease is more common in women (3.6:1 sex ratio). There are limited and systemic types of the disease, the latter, in addition to the skin, affects the muscular-articular apparatus, vessels and internal organs. Limited scleroderma is divided into morphea guttata, linear morphea, lichen sclerosus, idiopathic atrophoderma of Pasini and Pierini and acrosclerotic type. The morphea guttata is the most common form. The cases of bullous type of localized scleroderma are rare and found mainly in women during the menopause period, with bullae including transparent content appearing in the region of the skin’s induration and sclerosis loci. We present the clinical case of bullous scleroderma in a 63-year-old patient with histologically confirmed diagnosis of localized bullous scleroderma. The feature of the disease course in this patient was the appearance of a bullous element on the induration and sclerosis locus against the background of cytostatic therapy, which regressed after the addition of extracorporeal sorption methods to the therapy. This observation of localized bullous scleroderma demonstrates the successful application of extracorporeal sorption methods in combination with cytostatic therapy.
- 14 February 2024
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 23 (1)
Bullous scleroderma: experience of combined therapy
Scleroderma is an autoimmune disease manifested by damage to the connective tissue. The disease is more common in women (3.6:1 sex ratio). There are limited and systemic types of the disease, the latter, in addition to the skin, affects the muscular-articular apparatus, vessels and internal organs. Limited scleroderma is divided into morphea guttata, linear morphea, lichen sclerosus, idiopathic atrophoderma of Pasini and Pierini and acrosclerotic type. The morphea guttata is the most common form. The cases of bullous type of localized scleroderma are rare and found mainly in women during the menopause period, with bullae including transparent content appearing in the region of the skin’s induration and sclerosis loci. We present the clinical case of bullous scleroderma in a 63-year-old patient with histologically confirmed diagnosis of localized bullous scleroderma. The feature of the disease course in this patient was the appearance of a bullous element on the induration and sclerosis locus against the background of cytostatic therapy, which regressed after the addition of extracorporeal sorption methods to the therapy. This observation of localized bullous scleroderma demonstrates the successful application of extracorporeal sorption methods in combination with cytostatic therapy.
- 23 June 2023
- Published by Open Systems Publications in Лечащий врач
- No. 6(26)
Features of the formation of specific immunity after vaccination against viral hepatitis B in children and young people
According to the World Health Organization, there are about 300 million people worldwide living with chronic hepatitis B, with about 1.5 million new infections occurring each year. In the Russian Federation, starting from the new century, there has been a gradual decrease in the incidence of acute hepatitis B, which retains the status of a socially significant viral infection. Vaccination against hepatitis B was included in the National Immunization Schedule in December 1997. by order of the Ministry of Health of the Russian Federation No. 375, which was later (in September 1998) enshrined in the Federal Law "On Immunoprophylaxis of Infectious Diseases". Currently, the main indicator of the body's protection against infection with the hepatitis B virus after immunoprophylaxis is the level of post-vaccination antibodies of the IgG class to HBsAg (anti-HBs), which can be determined using serological tests. The results of a study of the intensity of post-vaccination immunity against hepatitis B in children and young people vaccinated in the first year of life with a monocomponent recombinant hepatitis B vaccine are presented. A high proportion of children (85.5%) with anti-hepatitis B indicators at low (10-100 mMU/ml) or practically undetectable (below 10 mMU/ml) has been established.ml) levels. The results obtained correlate with a high proportion of children with a burdened premorbid background (87.1%) and, probably, the presence of immunodeficiency conditions. In young people, the proportion of seronegativation was 43.2%, and in combination with persons with low-level antibodies - 82.8% of the total number of examined. Thus, due to the weak response to the recombinant hepatitis B vaccine and the high medical and social significance of hepatitis B infection, various approaches are currently being developed to enhance the effectiveness of vaccination: changes in the vaccination regimen; correction of immune system functions to restore an adequate response to vaccine preparations, the use of various adjuvants, including recombinant interferons.
- 23 June 2023
- Published by Open Systems Publications in Лечащий врач
- No. 6(26)
Features of the formation of specific immunity after vaccination against viral hepatitis B in children and young people
According to the World Health Organization, there are about 300 million people worldwide living with chronic hepatitis B, with about 1.5 million new infections occurring each year. In the Russian Federation, starting from the new century, there has been a gradual decrease in the incidence of acute hepatitis B, which retains the status of a socially significant viral infection. Vaccination against hepatitis B was included in the National Immunization Schedule in December 1997. by order of the Ministry of Health of the Russian Federation No. 375, which was later (in September 1998) enshrined in the Federal Law "On Immunoprophylaxis of Infectious Diseases". Currently, the main indicator of the body's protection against infection with the hepatitis B virus after immunoprophylaxis is the level of post-vaccination antibodies of the IgG class to HBsAg (anti-HBs), which can be determined using serological tests. The results of a study of the intensity of post-vaccination immunity against hepatitis B in children and young people vaccinated in the first year of life with a monocomponent recombinant hepatitis B vaccine are presented. A high proportion of children (85.5%) with anti-hepatitis B indicators at low (10-100 mMU/ml) or practically undetectable (below 10 mMU/ml) has been established.ml) levels. The results obtained correlate with a high proportion of children with a burdened premorbid background (87.1%) and, probably, the presence of immunodeficiency conditions. In young people, the proportion of seronegativation was 43.2%, and in combination with persons with low-level antibodies - 82.8% of the total number of examined. Thus, due to the weak response to the recombinant hepatitis B vaccine and the high medical and social significance of hepatitis B infection, various approaches are currently being developed to enhance the effectiveness of vaccination: changes in the vaccination regimen; correction of immune system functions to restore an adequate response to vaccine preparations, the use of various adjuvants, including recombinant interferons.
- 7 March 2023
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 22 (1)
Pathogenetic factors of acne in children and justification of systemic therapy
Acne is a common skin disease and usually begins in early puberty, less often later. The early onset of acne vulgaris is typical, often with the rapid formation of severe torpid forms of the disease. Therefore, it requires a timely pathogenesis-based strategy for treating and preventing recurrence. Special attention is drawn to the issue of childhood acne. The most effective drugs, in particular, systemic isotretinoin (SI), for treating acne are contraindicated in children under 12 years of age, which is a great challenge in managing such patients. We present a clinical case of extremely severe acne with rapid progression in a patient aged 11 years and justify the use of systemic isotretinoin. Clinical and laboratory monitoring confirmed the high clinical effectiveness of the therapy, which resulted in clinical regression of rashes after half the course dose with no significant side effects. Given the increase in severe acne in pediatric patients, further studies are needed on the safety profile of systemic isotretinoin for its introduction into pediatric practice.
- 7 March 2023
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 22 (1)
Pathogenetic factors of acne in children and justification of systemic therapy
Acne is a common skin disease and usually begins in early puberty, less often later. The early onset of acne vulgaris is typical, often with the rapid formation of severe torpid forms of the disease. Therefore, it requires a timely pathogenesis-based strategy for treating and preventing recurrence. Special attention is drawn to the issue of childhood acne. The most effective drugs, in particular, systemic isotretinoin (SI), for treating acne are contraindicated in children under 12 years of age, which is a great challenge in managing such patients. We present a clinical case of extremely severe acne with rapid progression in a patient aged 11 years and justify the use of systemic isotretinoin. Clinical and laboratory monitoring confirmed the high clinical effectiveness of the therapy, which resulted in clinical regression of rashes after half the course dose with no significant side effects. Given the increase in severe acne in pediatric patients, further studies are needed on the safety profile of systemic isotretinoin for its introduction into pediatric practice.
- 7 March 2023
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 22 (1)
Possibilities for assessment of age-related skin changes in aesthetic medicine. The role of ultrasonography
Assessment of skin condition is necessary for dermatologists and cosmetologists. While it is routine practice for dermatologists to assess the skin condition using physical and instrumental methods, cosmeticians rarely use additional skin examination methods. It may be partly due to a misunderstanding of the uses and capabilities of the various methods, and partly, it may be due to a desire to save time at a cosmetologist’s visit. Nevertheless, evaluation of age-related skin changes and assessment of the skin condition change after treatment is extremely important for targeted therapy. Therefore, the objective of the review was to summarize the current capabilities of clinical and instrumental diagnosis of age-related skin changes being the most common issue in the cosmetologists’ practice. This review addresses a variety of diagnostic methods, from the simplest to the most complex and invasive ones. Particular attention is paid to ultrasonic diagnostics of facial soft tissues, and recent evidence from Russian and foreign sources is systematized and generalized.
- 7 March 2023
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 22 (1)
Possibilities for assessment of age-related skin changes in aesthetic medicine. The role of ultrasonography
Assessment of skin condition is necessary for dermatologists and cosmetologists. While it is routine practice for dermatologists to assess the skin condition using physical and instrumental methods, cosmeticians rarely use additional skin examination methods. It may be partly due to a misunderstanding of the uses and capabilities of the various methods, and partly, it may be due to a desire to save time at a cosmetologist’s visit. Nevertheless, evaluation of age-related skin changes and assessment of the skin condition change after treatment is extremely important for targeted therapy. Therefore, the objective of the review was to summarize the current capabilities of clinical and instrumental diagnosis of age-related skin changes being the most common issue in the cosmetologists’ practice. This review addresses a variety of diagnostic methods, from the simplest to the most complex and invasive ones. Particular attention is paid to ultrasonic diagnostics of facial soft tissues, and recent evidence from Russian and foreign sources is systematized and generalized.
- Open Access
- 2 October 2022
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 21 (3) , 33-38
Longitudinal monitoring of post-vaccination immunity against hepatitis B in children after standard immunization in the first year of life and optimization of vaccination strategy
A clinical and laboratory examination of 62 children aged 10—17 years vaccinated against hepatitis B according to the standard scheme (0—1—6 months) in the first year of life strictly according to the National Calendar of preventive vaccinations in a standard dose (10 micrograms of recombinant HBsAg) with a monocomponent vaccine was carried out.The majority of children (58%) had indicators of seroconversion of HBsAg — anti-HBs-antibodies. This indicates the fact of long-lasting Grund immunity — 10—17 years after timely 3-fold immunization against hepatitis B according to the standard scheme at a standard dose (10 mcg of recombinant HBsAg in the first year of life in the absence of Wooster immunization (revaccination) in subsequent age periods, including children with a burdened premorbid background (87.1% among those observed). Since among those observed were children with invasive medical interventions (50%), the established fact reflects the protective effect of standard Grund immunization even in children at risk — with a positive parenteral history. At the same time, the total assessment of serological and molecular biological results found that after triple immunization against hepatitis B according to the standard scheme in the first year of life, out of 62 children aged 10—17 years, the proportion of seronegative was 42%. Low levels of antibodies (10—100 IU/l) were detected in 43% of cases, high (100—1000 IU/l) — in 15% of cases. No child had an antibody level exceeding >1000 IU/l. These results require the development of new approaches to immunization of children against hepatitis B with mandatory revaccination at an older age.
- 2 October 2022
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 21 (3) , 33-38
Open AccessLongitudinal monitoring of post-vaccination immunity against hepatitis B in children after standard immunization in the first year of life and optimization of vaccination strategy
A clinical and laboratory examination of 62 children aged 10—17 years vaccinated against hepatitis B according to the standard scheme (0—1—6 months) in the first year of life strictly according to the National Calendar of preventive vaccinations in a standard dose (10 micrograms of recombinant HBsAg) with a monocomponent vaccine was carried out.The majority of children (58%) had indicators of seroconversion of HBsAg — anti-HBs-antibodies. This indicates the fact of long-lasting Grund immunity — 10—17 years after timely 3-fold immunization against hepatitis B according to the standard scheme at a standard dose (10 mcg of recombinant HBsAg in the first year of life in the absence of Wooster immunization (revaccination) in subsequent age periods, including children with a burdened premorbid background (87.1% among those observed). Since among those observed were children with invasive medical interventions (50%), the established fact reflects the protective effect of standard Grund immunization even in children at risk — with a positive parenteral history. At the same time, the total assessment of serological and molecular biological results found that after triple immunization against hepatitis B according to the standard scheme in the first year of life, out of 62 children aged 10—17 years, the proportion of seronegative was 42%. Low levels of antibodies (10—100 IU/l) were detected in 43% of cases, high (100—1000 IU/l) — in 15% of cases. No child had an antibody level exceeding >1000 IU/l. These results require the development of new approaches to immunization of children against hepatitis B with mandatory revaccination at an older age.
- Open Access
- 6 October 2021
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 20 (3) , 29-32
Characteristics of post-vaccination immunity in students vaccinated against hepatitis B in the first year of life
Most researchers agree that the level of protective anti-HBs decreases with age after 3-fold immunization in the first year of life, which requires the introduction of a booster dose at least 5—7 years after the completed vaccination. It is necessary to continue monitoring those vaccinated against hepatitis B in the first year of life, including those from occupational risk groups.Objective: to assess the frequency and level of anti-HBs 18 or more years after the completed course of vaccination against hepatitis B according to the standard scheme in the first year of life and to identify risk groups that need revaccination.Of 116 donor students in Moscow, 18—22 years after the completed course of vaccination against hepatitis B according to the standard scheme carried out in the first year of life, in 42.3% of cases, the titer of specific antibodies was determined below the protective level (< 10 mME/ml). At the same time, the share of seronegative individuals among medical students was higher (52.8%). Of 116 donor students, in 38.8% of cases, the titer of protective antibodies was determined in low (10—100 mME/ml) and only in 13.8% — in high (100—1000 mME/ml) and in 5.2% — very high (> 1000 mME/ml) values. Markers of DNA HBV, HBsAg, and anti-HBcor were not detected in any cases. Medical students primarily need a revaccination against hepatitis B without a preliminary study of the initial titers of specific antibodies.
- 6 October 2021
- Published by Journal of Childrens Infections in CHILDREN INFECTIONS
- Vol. 20 (3) , 29-32
Open AccessCharacteristics of post-vaccination immunity in students vaccinated against hepatitis B in the first year of life
Most researchers agree that the level of protective anti-HBs decreases with age after 3-fold immunization in the first year of life, which requires the introduction of a booster dose at least 5—7 years after the completed vaccination. It is necessary to continue monitoring those vaccinated against hepatitis B in the first year of life, including those from occupational risk groups.Objective: to assess the frequency and level of anti-HBs 18 or more years after the completed course of vaccination against hepatitis B according to the standard scheme in the first year of life and to identify risk groups that need revaccination.Of 116 donor students in Moscow, 18—22 years after the completed course of vaccination against hepatitis B according to the standard scheme carried out in the first year of life, in 42.3% of cases, the titer of specific antibodies was determined below the protective level (< 10 mME/ml). At the same time, the share of seronegative individuals among medical students was higher (52.8%). Of 116 donor students, in 38.8% of cases, the titer of protective antibodies was determined in low (10—100 mME/ml) and only in 13.8% — in high (100—1000 mME/ml) and in 5.2% — very high (> 1000 mME/ml) values. Markers of DNA HBV, HBsAg, and anti-HBcor were not detected in any cases. Medical students primarily need a revaccination against hepatitis B without a preliminary study of the initial titers of specific antibodies.